{"gene":"NFKB2","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":1991,"finding":"The LYT-10 (NFKB2) protein contains an N-terminal rel (DNA-binding) domain homologous to NF-κB p50, a poly-G region, and C-terminal ankyrin-like repeat domains. The ankyrin domain inhibits DNA binding in vitro; removal of the ankyrin domain activates DNA binding to κB sequences. Chromosomal translocation-generated LYT-10–Cα1 fusion retains the rel domain, lacks the ankyrin domain, and binds κB sequences constitutively.","method":"cDNA cloning, in vitro DNA-binding assay (EMSA), domain deletion analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro DNA-binding reconstitution with domain deletion, foundational paper replicated by multiple subsequent studies","pmids":["1760839"],"is_preprint":false},{"year":1993,"finding":"NF-κB p100 (NFKB2/Lyt-10) functions as an IκB-like molecule: it is localized in the cytoplasm of HeLa cells where it associates with c-Rel, p50, and p65 (RelA), and its overexpression sequesters p65 in the cytoplasm, reducing nuclear p65 DNA-binding activity. p100 is also a component of the MHC class I transcription factor H2TF1.","method":"Subcellular fractionation, immunoblotting, EMSA, transient transfection reporter assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (fractionation, EMSA, co-immunoprecipitation, reporter assay), replicated across labs","pmids":["8413211"],"is_preprint":false},{"year":1993,"finding":"H2TF1, the ubiquitous MHC class I κB enhancer-binding factor, is the full-length p100 product (NF-κB2 p100) encoded by nfkb2. Purified H2TF1 binds the MHC κB site with high affinity (KD = 3 × 10⁻¹¹ M), contradicting earlier reports that p100 did not bind DNA.","method":"Affinity chromatography purification, peptide sequencing, specific antiserum reactivity, in vitro DNA-binding assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — protein purified to homogeneity, identified by peptide sequencing and specific antiserum, in vitro binding assay with KD determination","pmids":["8360178"],"is_preprint":false},{"year":1993,"finding":"NFKB2 p49/p52 forms a heterodimer with RelA (p65) that binds the HIV κB site with ~6-fold higher affinity (KD = 11.8 pM) than p49 homodimer alone (KD = 69.1 pM). The p49/p65 heterodimer stimulates in vitro transcription 18-fold. IκB-α (MAD-3) inhibits DNA binding of p49/p65 and p50/p65 heterodimers but stimulates binding of p49 or p50 alone.","method":"Scatchard analysis, in vitro transcription assay, recombinant protein binding assays, transient transfection","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — quantitative binding constants determined, in vitro transcription reconstituted, multiple methods in single rigorous study","pmids":["8441377"],"is_preprint":false},{"year":1994,"finding":"C-terminal truncations of NFKB2 found in lymphoid malignancies (p84/85 in HUT78 T-cell lymphoma) result in constitutive nuclear localization of the unprocessed protein, altered NF-κB complex composition, and loss of transcriptional repressor function; the truncated proteins bind κB sites but cannot repress NF-κB-mediated transcription.","method":"Northern blot, immunoprecipitation, EMSA, immunofluorescence, transient co-transfection reporter assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods, replicated across multiple laboratories with analogous tumor-derived constructs","pmids":["8208540","8036016"],"is_preprint":false},{"year":1994,"finding":"NFKB2 p100 is constitutively cytoplasmic; TPA-induced NF-κB activation causes cytoplasmic-to-nuclear translocation of the processed p52 form. p52 alone preferentially binds H2/HLA-κB sites over HIV/IgK-κB sites, but efficiently binds both when heterodimerized with RelA (p65). p52 homodimers have no intrinsic transactivation; they down-regulate p65-driven transcription, whereas p65/p52 heterodimers stimulate it.","method":"Immunofluorescence, EMSA, transient co-transfection reporter assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct localization experiments with functional consequence, EMSA binding specificity, reporter assays; replicated by multiple groups","pmids":["8108136"],"is_preprint":false},{"year":1994,"finding":"In HTLV-I–infected and Tax-expressing cells, NFKB2 (p100) is overexpressed and physically associated with c-Rel and with the Tax protein. Tax-dependent processing of p100 to p52 correlates with constitutive nuclear NF-κB activity, suggesting Tax drives NFKB2 processing as a mechanism of constitutive NF-κB activation.","method":"Co-immunoprecipitation, immunoblotting, EMSA","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-immunoprecipitation showing physical association, single lab, correlative processing data","pmids":["8108127"],"is_preprint":false},{"year":1995,"finding":"Tumor-associated NFKB2 mutants (p85 and lyt-10Cα) lacking the ankyrin domain are constitutively nuclear, bind κB sites in unprocessed form, activate transcription via heterodimerization with RelA/p65, and have lost the transcriptional repression activity of normal p52. They can independently transactivate κB reporter genes in a manner not further stimulated by Bcl-3.","method":"Immunofluorescence, UV-crosslinking immunoprecipitation of DNA-protein adducts, transient co-transfection reporter assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal functional assays (localization, DNA binding, transcriptional activation/repression), replicated across labs","pmids":["7651435"],"is_preprint":false},{"year":1995,"finding":"Overexpressed p100 (NFKB2) in human breast cancer cells sequesters p50/p65 heterodimers in the cytoplasm via co-immunoprecipitation, acting as a cytoplasmic IκB-like inhibitor; most p65 is complexed with p100 rather than IκB-α in high-p100 cells.","method":"Co-immunoprecipitation, immunoblotting, subcellular fractionation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-immunoprecipitation from endogenous proteins in cell lines, consistent with mechanistic model from other studies","pmids":["7478612"],"is_preprint":false},{"year":1995,"finding":"The NFKB2 promoter contains six κB sites (five capable of binding NF-κB complexes in vitro). RelA transactivates the NFKB2 promoter in a dose-dependent manner, while NF-κB p52 acts as a repressor of its own gene promoter, establishing a negative feedback regulatory circuit.","method":"EMSA, transient transfection with CAT reporter, co-transfection with NF-κB effector plasmids","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter-reporter and EMSA experiments, single lab","pmids":["7541912"],"is_preprint":false},{"year":1999,"finding":"p52 is generated principally by cotranslational proteasomal processing of p100, dependent on a glycine-rich region (GRR) upstream of the p52 C-terminus; repositioning the GRR alters the site of proteasome cleavage. Sequences downstream of the GRR, flanking the processing site, confer the characteristically inefficient p52 generation from p100 compared to the balanced p50/p105 processing of NFKB1.","method":"p100/p105 chimera constructs, proteasome inhibitor experiments, immunoblotting, in vitro translation","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — biochemical reconstitution with chimeric constructs and domain repositioning establishing mechanistic determinants of processing","pmids":["10597218"],"is_preprint":false},{"year":2009,"finding":"p100 assembles into high-molecular-weight complexes in the cytoplasm that bind NF-κB subunits in two modes: (1) direct dimerization via Rel homology domains and (2) interaction of p100 ankyrin repeats with preformed NF-κB dimers, thereby mediating bona fide IκBδ activity. These complexes regulate all NF-κB isoforms.","method":"Biochemical characterization of endogenous cytoplasmic complexes, purified recombinant protein reconstitution, gel filtration, immunoprecipitation","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — both endogenous and purified recombinant proteins used, multiple binding modes identified biochemically, rigorous reconstitution","pmids":["19524538"],"is_preprint":false},{"year":2007,"finding":"A point mutation in Nfkb2 that prevents processing of p100 to p52 generates a 'super-repressor' phenotype: signaling through the noncanonical pathway is ablated due to p52 absence, causing disorganized splenic architecture and disrupted B cell development. Furthermore, the unprocessed p100 interacts with RelA, preventing RelA dimer activation in response to both canonical and noncanonical stimuli, resulting in defective lymph node formation and altered bone homeostasis.","method":"Mouse genetic model (knock-in point mutation), immunoblotting, histological analysis, signaling assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — defined genetic model with specific molecular and cellular phenotypic readouts, establishes p100 as inhibitor of RelA","pmids":["18025196"],"is_preprint":false},{"year":2012,"finding":"SCF(Fbw7) is the E3 ubiquitin ligase that governs ubiquitination and proteasomal destruction of NFkB2/p100 in a GSK3-dependent manner. In Fbw7-null cells, elevated p100 reduces NFkB signaling and increases TNFα-induced cell death; reintroduction of wild-type but not disease-derived mutant Fbw7 rescues NFkB activity. T cell-specific Fbw7 depletion reduces NFkB activity and perturbs T cell differentiation.","method":"Genetic knockout cells (Fbw7-/-), immunoblotting, ubiquitination assay, T cell-specific conditional knockout mouse model","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function genetic model, rescue with wild-type vs. mutant Fbw7, in vivo T cell model, multiple orthogonal methods","pmids":["22708077"],"is_preprint":false},{"year":2013,"finding":"Heterozygous C-terminal frameshift and nonsense mutations in NFKB2 (p.Lys855Serfs*7 and p.Arg853*) affect phosphorylation and proteasomal processing of p100, blocking p52 nuclear translocation. This establishes the noncanonical NF-κB signaling pathway as a genetic cause of common variable immunodeficiency.","method":"Exome sequencing, immunoblot analysis, immunofluorescence microscopy of patient B cells","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct functional analysis of patient-derived cells with two orthogonal methods (immunoblot and immunofluorescence), replicated in subsequent studies","pmids":["24140114"],"is_preprint":false},{"year":2014,"finding":"A missense mutation (D865G) in NFKB2 causes failure of p100 phosphorylation, blocking its processing to p52 and disrupting both canonical and noncanonical NF-κB pathways; this leads to severe mature and transitional B-cell deficiency.","method":"Western blotting, immunophenotyping, patient-derived cells","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional demonstration of phosphorylation failure and processing block in patient cells, single lab","pmids":["25237204"],"is_preprint":false},{"year":2014,"finding":"An 8 bp C-terminal frameshift deletion in NFKB2 (p.Asp865Valfs*17) mutates Ser866 to Arg, leaving p100 unphosphorylated at this critical regulatory position, thereby abrogating p100 processing and nuclear translocation of p52.","method":"Western blot, Sanger sequencing, flow cytometry (B cell immunophenotyping), patient cell analysis","journal":"Journal of clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphorylation and processing defects demonstrated directly in patient cells, identifies specific regulatory phosphorylation site","pmids":["24888602"],"is_preprint":false},{"year":2015,"finding":"NF-κB2/p52 directly transcriptionally activates EZH2 expression in melanoma cells. Inhibition of the noncanonical NF-κB pathway by targeting NF-kB2/p52 or the upstream kinase NIK decreases EZH2, restoring the senescence program. Overexpression of NF-kB2/p52 in normal melanocytes prevents stress- and oncogene-induced senescence.","method":"siRNA knockdown, overexpression, mouse xenograft models, ChIP/transcriptional activation assays (implied by direct transcriptional activation claim)","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional loss-of-function and gain-of-function with defined cellular phenotype (senescence), in vivo validation, single lab","pmids":["26364600"],"is_preprint":false},{"year":2017,"finding":"Novel nonsense NFKB2 mutations within the Rel homology domain (E418X and R635X) cause constitutive nuclear localization of truncated proteins and activation of both canonical and noncanonical NF-κB pathways, distinct from C-terminal mutations that produce unprocessable p100 super-repressor.","method":"Flow cytometry, immunoblotting, immunohistochemistry, luciferase reporter assay, real-time PCR, multiplex cytokine assay in transfected HEK293T cells and patient PBMCs","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods including functional reporter assays and patient cell studies, defines distinct gain-of-function mechanism","pmids":["28778864"],"is_preprint":false},{"year":2021,"finding":"Nfkb2-mediated noncanonical signaling in intestinal epithelial cells escalates the RelA-driven proinflammatory gene response by supplementing latent NF-κB dimers to the canonical module, exacerbating inflammatory cell infiltration and colon pathologies. Cell-autonomous Nfkb2 signaling increases available latent NF-κB dimers, linking noncanonical signaling to canonical RelA-driven inflammation.","method":"Mouse model of experimental colitis, conditional intestinal epithelial cell-specific genetic manipulation, mechanistic studies of latent dimer supplementation","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in cell-specific mouse model, defined molecular mechanism (latent dimer supplementation), specific phenotypic readout","pmids":["34155144"],"is_preprint":false},{"year":2021,"finding":"Severe p100-degradation resistance (due to mutations in the p100 degron required for signal-dependent degradation) causes thymic medullary hypoplasia and autoimmune disease, while absence of both p100 and p52 does not. Autoimmunity arises from the IκB function of degradation-resistant p100 in nonhematopoietic cells, not from p52 deficiency.","method":"Mouse genetic models with graded degron mutations, thymic histology, T cell receptor repertoire analysis, bone marrow transplantation","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple allelic series establishing mechanistic hierarchy, epistasis with p100-/- mice, nonhematopoietic cell function established by transplantation","pmids":["33107914"],"is_preprint":false},{"year":2024,"finding":"NFKB2 mutations directly impair human pituitary corticotroph development: pituitary organoids derived from CRISPR/Cas9-edited hiPSCs harboring DAVID patient NFKB2 mutations show changes in pituitary progenitor genes (HESX1, PITX1, LHX3), hypothalamic secreted factors (BMP4, FGF8, FGF10), lineage precursor genes (TBX19, POU1F1), and corticotroph terminal differentiation markers (PCSK1, POMC), with drastic reduction in corticotroph numbers.","method":"CRISPR/Cas9-edited human iPSC-derived pituitary organoids, gene expression analysis","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR-edited human disease model with specific molecular readouts, establishes direct causal role of NFKB2 in pituitary differentiation","pmids":["39607428"],"is_preprint":false},{"year":2026,"finding":"B3GNT3 physically interacts with NFKB2/p100 and facilitates its phosphorylation, processing into p52, and nuclear accumulation, thereby activating noncanonical NF-κB signaling. This interaction is independent of B3GNT3 glycosyltransferase activity. Genetic ablation of NFKB2 reverses the oncogenic effects of B3GNT3.","method":"Co-immunoprecipitation coupled with mass spectrometry, co-IP, catalytic inactive mutant of B3GNT3, NFKB2 knockout, immunoblotting, xenograft models","journal":"Cellular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP with MS identification, catalytic mutant analysis, genetic rescue, single lab","pmids":["41838238"],"is_preprint":false},{"year":2025,"finding":"TRAIL-induced cytokine production (CXCLs 1, 2, 3, 8, 11 and IL-6) in triple negative breast cancer cells is mediated predominantly through death receptor 5, caspase-8, and the noncanonical NFKB2 pathway. These cytokines promote neutrophil chemotaxis and immune suppression. In vivo TRAIL treatment activates the NFkB2 pathway, elevates cytokine production, and increases neutrophil tumor recruitment.","method":"RNAseq, siRNA knockdown, in vitro neutrophil chemotaxis assays, TNBC xenograft mouse models, immunoblotting","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway knockdown with defined cytokine readout, in vivo validation, multiple cell lines tested, single lab","pmids":["40187604"],"is_preprint":false}],"current_model":"NFKB2 encodes the precursor p100 and processed p52: p100 contains an N-terminal rel/DNA-binding domain and C-terminal ankyrin repeats that function as an IκBδ-like inhibitor by sequestering NF-κB dimers (including RelA) in the cytoplasm as part of high-molecular-weight complexes; signal-dependent phosphorylation at C-terminal sites (including Ser866) triggers GSK3-dependent recognition by the SCF(Fbw7) E3 ligase and proteasomal processing that releases p52, which translocates to the nucleus as an active transcription factor preferentially forming heterodimers with RelB or RelA to activate κB target genes; p52 also auto-represses NFKB2 transcription via a negative feedback loop; C-terminal truncating mutations abolish the ankyrin/IκBδ function producing constitutively nuclear, constitutively active oncoproteins, while specific C-terminal phosphorylation-site mutations generate non-processable p100 super-repressors that block both canonical and noncanonical NF-κB signaling, causing immunodeficiency (CVID/DAVID syndrome) and autoimmunity through degradation-resistant p100 IκBδ activity in nonhematopoietic cells including thymic stroma and pituitary progenitors."},"narrative":{"mechanistic_narrative":"NFKB2 encodes a bifunctional NF-κB precursor, p100, whose N-terminal Rel homology domain confers κB-site DNA binding while its C-terminal ankyrin repeats act as an intramolecular and intermolecular IκB-like inhibitor [PMID:1760839, PMID:8413211]. In its full-length cytoplasmic form, p100 (identical to the MHC class I enhancer factor H2TF1) sequesters NF-κB subunits including c-Rel, p50, and RelA/p65, both by direct Rel-domain dimerization and by capturing preformed dimers through its ankyrin repeats—the basis of its bona fide IκBδ activity within high-molecular-weight complexes that restrain all NF-κB isoforms [PMID:8413211, PMID:8360178, PMID:7478612, PMID:19524538]. Signal-dependent processing removes the ankyrin domain to release the active p52 subunit: p52 has no intrinsic transactivation and homodimers repress transcription, but p52/RelA heterodimers bind κB sites with high affinity and strongly activate transcription [PMID:8441377, PMID:8108136]. Processing proceeds via cotranslational proteasomal cleavage gated by a glycine-rich region [PMID:10597218] and is controlled by C-terminal phosphorylation (including Ser866) that licenses GSK3-dependent, SCF(Fbw7)-mediated ubiquitination and degradation of the inhibitory C-terminus [PMID:22708077, PMID:24888602]. p52 also represses the NFKB2 promoter, forming a negative feedback loop that opposes RelA-driven transactivation of the gene [PMID:7541912]. Two distinct classes of disease-causing mutation illustrate this architecture: C-terminal truncating or phosphorylation-site mutations that block processing generate degradation-resistant p100 \"super-repressors\" which inhibit RelA and ablate both canonical and noncanonical signaling [PMID:18025196, PMID:24140114, PMID:33107914], whereas Rel-domain nonsense mutations remove the ankyrin domain to yield constitutively nuclear, transcriptionally active species [PMID:7651435, PMID:28778864]. NFKB2 mutations cause common variable immunodeficiency, and the IκBδ activity of degradation-resistant p100 in nonhematopoietic cells—including thymic stroma and pituitary corticotroph progenitors—drives autoimmunity and the endocrine features of DAVID syndrome [PMID:24140114, PMID:33107914, PMID:39607428].","teleology":[{"year":1991,"claim":"Established the domain logic of NFKB2: an N-terminal Rel DNA-binding domain held in check by C-terminal ankyrin repeats, answering how one gene product could be both a transcription factor and an inhibitor.","evidence":"cDNA cloning and in vitro EMSA with domain deletions; translocation-derived ankyrin-less fusion","pmids":["1760839"],"confidence":"High","gaps":["Did not resolve how the ankyrin domain is removed in cells","No in vivo processing mechanism"]},{"year":1993,"claim":"Defined p100 as a cytoplasmic IκB-like sequestering molecule and identified it as the MHC class I enhancer factor H2TF1, reconciling its inhibitory and DNA-binding identities.","evidence":"Subcellular fractionation, co-IP, EMSA, affinity purification with peptide sequencing and KD determination in HeLa cells","pmids":["8413211","8360178"],"confidence":"High","gaps":["Did not define the signal that releases sequestered dimers","Endogenous complex stoichiometry unresolved"]},{"year":1993,"claim":"Showed that processed p52 acquires activating function only through heterodimerization, distinguishing repressive homodimers from transactivating p52/RelA complexes.","evidence":"Scatchard analysis, in vitro transcription, recombinant binding assays","pmids":["8441377"],"confidence":"High","gaps":["In vitro affinities not linked to cellular target gene selectivity"]},{"year":1994,"claim":"Demonstrated that signal-induced processing converts cytoplasmic p100 to nuclear p52, and that tumor-derived C-terminal truncations abolish repression while remaining DNA-binding—linking ankyrin loss to oncogenic constitutive activity.","evidence":"Immunofluorescence, EMSA, reporter assays, tumor-derived constructs (HUT78 p84/85)","pmids":["8108136","8208540","8036016"],"confidence":"High","gaps":["Processing protease and signaling input not yet identified","Mechanism of constitutive nuclear retention undefined"]},{"year":1994,"claim":"Connected viral oncogenesis to NFKB2, showing HTLV-I Tax associates with p100 and drives its processing to sustain constitutive NF-κB activity.","evidence":"Co-IP, immunoblotting, EMSA in Tax-expressing cells","pmids":["8108127"],"confidence":"Medium","gaps":["Correlative processing data, single lab","Direct Tax-induced cleavage not reconstituted"]},{"year":1995,"claim":"Identified the NFKB2 promoter negative feedback loop—RelA activates the gene while p52 represses it—explaining homeostatic control of pathway output.","evidence":"EMSA and CAT reporter co-transfection with NF-κB effectors","pmids":["7541912"],"confidence":"Medium","gaps":["Single lab promoter-reporter assays","In vivo relevance of feedback not tested"]},{"year":1999,"claim":"Defined the cis-determinants of inefficient p100 processing, showing a glycine-rich region directs cotranslational proteasomal cleavage and flanking sequences limit p52 yield.","evidence":"p100/p105 chimeras, proteasome inhibitors, in vitro translation","pmids":["10597218"],"confidence":"High","gaps":["Did not identify the E3 ligase or signal that triggers processing"]},{"year":2009,"claim":"Resolved the biochemical basis of IκBδ activity, showing p100 forms high-MW complexes binding NF-κB via two modes (Rel dimerization and ankyrin capture of preformed dimers) that regulate all isoforms.","evidence":"Endogenous complex characterization, recombinant reconstitution, gel filtration, IP","pmids":["19524538"],"confidence":"High","gaps":["Structural model of the complex not determined","Dynamics of release upon signaling not captured"]},{"year":2007,"claim":"Established in vivo that unprocessable p100 acts as a super-repressor of RelA, demonstrating p100 inhibits canonical as well as noncanonical signaling and is required for lymphoid organ development.","evidence":"Nfkb2 processing-deficient knock-in mouse, histology, signaling assays","pmids":["18025196"],"confidence":"High","gaps":["Phosphorylation/degron details of the block not molecularly mapped"]},{"year":2012,"claim":"Identified SCF(Fbw7) as the GSK3-dependent E3 ligase governing p100 degradation, closing the loop from C-terminal phosphorylation to proteasomal turnover.","evidence":"Fbw7-null cells, ubiquitination assays, rescue with WT vs mutant Fbw7, T cell conditional knockout","pmids":["22708077"],"confidence":"High","gaps":["Precise phosphodegron residues recognized by Fbw7 not fully enumerated","Kinase upstream of GSK3 priming not defined here"]},{"year":2013,"claim":"Established NFKB2 C-terminal mutations as a genetic cause of common variable immunodeficiency by showing they block p100 phosphorylation, processing, and p52 nuclear translocation.","evidence":"Exome sequencing, immunoblot and immunofluorescence of patient B cells","pmids":["24140114"],"confidence":"High","gaps":["Tissue-specific contributions to disease not dissected in patients"]},{"year":2014,"claim":"Pinpointed Ser866 as the critical regulatory phosphorylation site, with missense and frameshift mutations abolishing its phosphorylation to block processing and cause B-cell deficiency.","evidence":"Western blot, immunophenotyping, Sanger sequencing of patient cells (D865G; D865Vfs*17)","pmids":["25237204","24888602"],"confidence":"Medium","gaps":["Single-lab patient analyses","Kinase phosphorylating Ser866 not identified"]},{"year":2017,"claim":"Distinguished a second mutational class—Rel-domain nonsense mutations—that produce constitutively nuclear gain-of-function proteins activating both pathways, contrasting with C-terminal loss-of-function super-repressors.","evidence":"Reporter assays, immunoblot, IHC, cytokine assays in HEK293T and patient PBMCs (E418X, R635X)","pmids":["28778864"],"confidence":"High","gaps":["Clinical penetrance differences between mutation classes not fully resolved"]},{"year":2021,"claim":"Established that degradation-resistant p100, not p52 loss, drives autoimmunity, acting through IκB function in nonhematopoietic cells and causing thymic medullary hypoplasia.","evidence":"Graded degron-mutant mouse allelic series, thymic histology, TCR repertoire, bone marrow transplantation","pmids":["33107914"],"confidence":"High","gaps":["Specific thymic stromal targets of p100 IκB activity not enumerated"]},{"year":2021,"claim":"Showed noncanonical Nfkb2 signaling amplifies canonical RelA-driven inflammation by supplying latent NF-κB dimers, providing a crosstalk mechanism in intestinal epithelium.","evidence":"Intestinal epithelial cell-specific conditional mouse colitis model with epistasis analysis","pmids":["34155144"],"confidence":"High","gaps":["Quantitative contribution of dimer supplementation to human disease unknown"]},{"year":2024,"claim":"Demonstrated a direct, cell-autonomous role for NFKB2 in human pituitary corticotroph development, explaining the endocrine features of DAVID syndrome.","evidence":"CRISPR-edited DAVID-mutant hiPSC pituitary organoids, gene expression analysis","pmids":["39607428"],"confidence":"High","gaps":["Direct transcriptional targets of NFKB2 in corticotrophs not mapped"]},{"year":2025,"claim":"Linked NFKB2 to tumor immune evasion, showing TRAIL/DR5/caspase-8 signaling engages the noncanonical pathway to drive chemokine production and neutrophil recruitment in TNBC.","evidence":"RNAseq, siRNA knockdown, chemotaxis assays, TNBC xenografts, immunoblot","pmids":["40187604"],"confidence":"Medium","gaps":["Single-lab study","Direct NFKB2-driven chemokine gene occupancy not shown"]},{"year":2026,"claim":"Identified B3GNT3 as a noncatalytic interactor that promotes p100 phosphorylation and processing, defining a new upstream activator of noncanonical signaling in cancer.","evidence":"Reciprocal co-IP/MS, catalytic-inactive B3GNT3 mutant, NFKB2 knockout rescue, xenografts","pmids":["41838238"],"confidence":"Medium","gaps":["Single lab; mechanism by which B3GNT3 promotes phosphorylation undefined","Reciprocal validation in physiological context limited"]},{"year":null,"claim":"The identity of the kinase that phosphorylates Ser866 to prime SCF(Fbw7) recognition, and the structural basis of p100 IκBδ high-MW complexes, remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["Ser866 kinase not identified in the corpus","No structural model of the p100–NF-κB inhibitory complex","Tissue-specific nonhematopoietic target genes incompletely defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3,5,9,17]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,3,5]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,8,11,12]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[1,8,11]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,5,8,11]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,5,7,18]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,12,19]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,5,9,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[12,14,19,20]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[14,18,20,21]}],"complexes":["NF-κB p52/RelA heterodimer","p100 IκBδ high-molecular-weight complex","H2TF1"],"partners":["RELA","RELB","REL","NFKB1","FBXW7","B3GNT3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q00653","full_name":"Nuclear factor NF-kappa-B p100 subunit","aliases":["DNA-binding factor KBF2","H2TF1","Lymphocyte translocation chromosome 10 protein","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2","Oncogene Lyt-10","Lyt10"],"length_aa":900,"mass_kda":96.7,"function":"NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-BMAL1 heterodimer","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q00653/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NFKB2","classification":"Not Classified","n_dependent_lines":67,"n_total_lines":1208,"dependency_fraction":0.055463576158940396},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000077150","cell_line_id":"CID001700","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":1}],"interactors":[{"gene":"NFKB1","stoichiometry":10.0},{"gene":"RELA","stoichiometry":4.0},{"gene":"RELB","stoichiometry":0.2},{"gene":"NFKBIA","stoichiometry":0.2},{"gene":"REL","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001700","total_profiled":1310},"omim":[{"mim_id":"620449","title":"IMMUNODEFICIENCY 112; IMD112","url":"https://www.omim.org/entry/620449"},{"mim_id":"619289","title":"ZINC FINGER PROTEIN 91, ATYPICAL E3 UBIQUITIN LIGASE; ZFP91","url":"https://www.omim.org/entry/619289"},{"mim_id":"616704","title":"COMM DOMAIN-CONTAINING PROTEIN 10; COMMD10","url":"https://www.omim.org/entry/616704"},{"mim_id":"616701","title":"COMM DOMAIN-CONTAINING PROTEIN 4; COMMD4","url":"https://www.omim.org/entry/616701"},{"mim_id":"616699","title":"COMM DOMAIN-CONTAINING PROTEIN 2; COMMD2","url":"https://www.omim.org/entry/616699"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Cytosol","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/NFKB2"},"hgnc":{"alias_symbol":["LYT-10","p52","p105","NF-kB2","p49/p100"],"prev_symbol":[]},"alphafold":{"accession":"Q00653","domains":[{"cath_id":"2.60.40.340","chopping":"40-142_188-219","consensus_level":"high","plddt":90.2663,"start":40,"end":219},{"cath_id":"2.60.40.10","chopping":"231-330","consensus_level":"high","plddt":91.7906,"start":231,"end":330},{"cath_id":"1.10.533.10","chopping":"773-846","consensus_level":"high","plddt":79.8616,"start":773,"end":846}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q00653","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q00653-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q00653-F1-predicted_aligned_error_v6.png","plddt_mean":74.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NFKB2","jax_strain_url":"https://www.jax.org/strain/search?query=NFKB2"},"sequence":{"accession":"Q00653","fasta_url":"https://rest.uniprot.org/uniprotkb/Q00653.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q00653/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q00653"}},"corpus_meta":[{"pmid":"1760839","id":"PMC_1760839","title":"B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50.","date":"1991","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/1760839","citation_count":403,"is_preprint":false},{"pmid":"24140114","id":"PMC_24140114","title":"Germline mutations in NFKB2 implicate the noncanonical NF-κB pathway in the pathogenesis of common variable immunodeficiency.","date":"2013","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24140114","citation_count":197,"is_preprint":false},{"pmid":"19524538","id":"PMC_19524538","title":"The Nfkb1 and Nfkb2 proteins p105 and p100 function as the core of high-molecular-weight heterogeneous complexes.","date":"2009","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/19524538","citation_count":132,"is_preprint":false},{"pmid":"8441377","id":"PMC_8441377","title":"Dimerization of NF-KB2 with RelA(p65) regulates DNA binding, transcriptional activation, and inhibition by an I kappa B-alpha (MAD-3).","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8441377","citation_count":128,"is_preprint":false},{"pmid":"7478612","id":"PMC_7478612","title":"Highly-expressed p100/p52 (NFKB2) sequesters other NF-kappa B-related proteins in the cytoplasm of human breast cancer cells.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7478612","citation_count":122,"is_preprint":false},{"pmid":"8413211","id":"PMC_8413211","title":"NF-kappa B p100 (Lyt-10) is a component of H2TF1 and can function as an I kappa B-like molecule.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8413211","citation_count":121,"is_preprint":false},{"pmid":"30941118","id":"PMC_30941118","title":"Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30941118","citation_count":118,"is_preprint":false},{"pmid":"8378093","id":"PMC_8378093","title":"Structural alterations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies.","date":"1993","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8378093","citation_count":117,"is_preprint":false},{"pmid":"10597218","id":"PMC_10597218","title":"The generation of nfkb2 p52: mechanism and efficiency.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10597218","citation_count":91,"is_preprint":false},{"pmid":"7949142","id":"PMC_7949142","title":"Heterogeneous chromosomal aberrations generate 3' truncations of the NFKB2/lyt-10 gene in lymphoid malignancies.","date":"1994","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7949142","citation_count":90,"is_preprint":false},{"pmid":"7541912","id":"PMC_7541912","title":"Structural and functional characterization of the promoter regions of the NFKB2 gene.","date":"1995","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/7541912","citation_count":83,"is_preprint":false},{"pmid":"25237204","id":"PMC_25237204","title":"Autosomal-dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in nonprocessable p100.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25237204","citation_count":82,"is_preprint":false},{"pmid":"8036016","id":"PMC_8036016","title":"Rearrangement and altered expression of the NFKB-2 gene in human cutaneous T-lymphoma cells.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8036016","citation_count":80,"is_preprint":false},{"pmid":"8108127","id":"PMC_8108127","title":"Overproduction of NFKB2 (lyt-10) and c-Rel: a mechanism for HTLV-I Tax-mediated trans-activation via the NF-kappa B signalling pathway.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8108127","citation_count":77,"is_preprint":false},{"pmid":"7651435","id":"PMC_7651435","title":"Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7651435","citation_count":76,"is_preprint":false},{"pmid":"22708077","id":"PMC_22708077","title":"SCF(Fbw7) modulates the NFkB signaling pathway by targeting NFkB2 for ubiquitination and destruction.","date":"2012","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/22708077","citation_count":75,"is_preprint":false},{"pmid":"18025196","id":"PMC_18025196","title":"A novel mutation in the Nfkb2 gene generates an NF-kappa B2 \"super repressor\".","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18025196","citation_count":69,"is_preprint":false},{"pmid":"25524009","id":"PMC_25524009","title":"Mutations in NFKB2 and potential genetic heterogeneity in patients with DAVID syndrome, having variable endocrine and immune deficiencies.","date":"2014","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25524009","citation_count":67,"is_preprint":false},{"pmid":"24888602","id":"PMC_24888602","title":"Novel NFKB2 mutation in early-onset CVID.","date":"2014","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24888602","citation_count":64,"is_preprint":false},{"pmid":"8208540","id":"PMC_8208540","title":"Rearranged NFKB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8208540","citation_count":62,"is_preprint":false},{"pmid":"28778864","id":"PMC_28778864","title":"Novel nonsense gain-of-function NFKB2 mutations associated with a combined immunodeficiency phenotype.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28778864","citation_count":60,"is_preprint":false},{"pmid":"25205549","id":"PMC_25205549","title":"Combined immune deficiency in a patient with a novel NFKB2 mutation.","date":"2014","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25205549","citation_count":53,"is_preprint":false},{"pmid":"8108136","id":"PMC_8108136","title":"Mechanism of expression and role in transcriptional control of the proto-oncogene NFKB-2/LYT-10.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8108136","citation_count":50,"is_preprint":false},{"pmid":"34155144","id":"PMC_34155144","title":"An epithelial Nfkb2 pathway exacerbates intestinal inflammation by supplementing latent RelA dimers to the canonical NF-κB module.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34155144","citation_count":49,"is_preprint":false},{"pmid":"15629778","id":"PMC_15629778","title":"High levels of p105 (NFKB1) and p100 (NFKB2) proteins in HPV16-transformed keratinocytes: role of E6 and E7 oncoproteins.","date":"2005","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/15629778","citation_count":47,"is_preprint":false},{"pmid":"27749582","id":"PMC_27749582","title":"NFKB2 mutation in common variable immunodeficiency and isolated adrenocorticotropic hormone deficiency: A case report and review of literature.","date":"2016","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27749582","citation_count":46,"is_preprint":false},{"pmid":"1612589","id":"PMC_1612589","title":"Related subunits of NF-kappa B map to two distinct loci associated with translocations in leukemia, NFKB1 and NFKB2.","date":"1992","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1612589","citation_count":45,"is_preprint":false},{"pmid":"26364600","id":"PMC_26364600","title":"NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26364600","citation_count":44,"is_preprint":false},{"pmid":"1427874","id":"PMC_1427874","title":"Chromosomal localization of the genes encoding the p50/p105 subunits of NF-kappa B (NFKB2) and the I kappa B/MAD-3 (NFKBI) inhibitor of NF-kappa B to 4q24 and 14q13, respectively.","date":"1992","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1427874","citation_count":44,"is_preprint":false},{"pmid":"9150386","id":"PMC_9150386","title":"Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9150386","citation_count":40,"is_preprint":false},{"pmid":"9021684","id":"PMC_9021684","title":"The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies.","date":"1996","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/9021684","citation_count":30,"is_preprint":false},{"pmid":"20598117","id":"PMC_20598117","title":"Myc suppression of Nfkb2 accelerates lymphomagenesis.","date":"2010","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20598117","citation_count":28,"is_preprint":false},{"pmid":"9529131","id":"PMC_9529131","title":"Regulation of p100 (NFKB2) expression in human monocytes in response to inflammatory mediators and lymphokines.","date":"1998","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/9529131","citation_count":26,"is_preprint":false},{"pmid":"8360178","id":"PMC_8360178","title":"Purification of the major histocompatibility complex class I transcription factor H2TF1. The full-length product of the nfkb2 gene.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8360178","citation_count":26,"is_preprint":false},{"pmid":"9417912","id":"PMC_9417912","title":"Identification of a novel gene, PSD, adjacent to NFKB2/lyt-10, which contains Sec7 and pleckstrin-homology domains.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9417912","citation_count":25,"is_preprint":false},{"pmid":"31417880","id":"PMC_31417880","title":"Novel Heterozygous Mutation in NFKB2 Is Associated With Early Onset CVID and a Functional Defect in NK Cells Complicated by Disseminated CMV Infection and Severe Nephrotic Syndrome.","date":"2019","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/31417880","citation_count":25,"is_preprint":false},{"pmid":"33107914","id":"PMC_33107914","title":"Nfkb2 variants reveal a p100-degradation threshold that defines autoimmune susceptibility.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33107914","citation_count":24,"is_preprint":false},{"pmid":"36509151","id":"PMC_36509151","title":"NFKB2 haploinsufficiency identified via screening for IFN-α2 autoantibodies in children and adolescents hospitalized with SARS-CoV-2-related complications.","date":"2022","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36509151","citation_count":22,"is_preprint":false},{"pmid":"7597296","id":"PMC_7597296","title":"bcl-1, bcl-2, p53, c-myc, and lyt-10 analysis in cutaneous lymphomas.","date":"1995","source":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer","url":"https://pubmed.ncbi.nlm.nih.gov/7597296","citation_count":22,"is_preprint":false},{"pmid":"35625776","id":"PMC_35625776","title":"Targeting TKI-Activated NFKB2-MIF/CXCLs-CXCR2 Signaling Pathways in FLT3 Mutated Acute Myeloid Leukemia Reduced Blast Viability.","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/35625776","citation_count":21,"is_preprint":false},{"pmid":"32152480","id":"PMC_32152480","title":"NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32152480","citation_count":20,"is_preprint":false},{"pmid":"31751612","id":"PMC_31751612","title":"NFKB2 regulates human Tfh and Tfr pool formation and germinal center potential.","date":"2019","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/31751612","citation_count":19,"is_preprint":false},{"pmid":"20708837","id":"PMC_20708837","title":"Role of NFKB2 on the early myeloid differentiation of CD34+ hematopoietic stem/progenitor cells.","date":"2010","source":"Differentiation; research in biological diversity","url":"https://pubmed.ncbi.nlm.nih.gov/20708837","citation_count":18,"is_preprint":false},{"pmid":"28472507","id":"PMC_28472507","title":"A Case Report of Hypoglycemia and Hypogammaglobulinemia: DAVID Syndrome in a Patient With a Novel NFKB2 Mutation.","date":"2017","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28472507","citation_count":18,"is_preprint":false},{"pmid":"28368397","id":"PMC_28368397","title":"Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28368397","citation_count":17,"is_preprint":false},{"pmid":"10713675","id":"PMC_10713675","title":"Transcriptional regulatory effects of lymphoma-associated NFKB2/lyt10 protooncogenes.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10713675","citation_count":17,"is_preprint":false},{"pmid":"37520713","id":"PMC_37520713","title":"IRP1 mediated ferroptosis reverses temozolomide resistance in glioblastoma via affecting LCN2/FPN1 signaling axis depended on NFKB2.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/37520713","citation_count":16,"is_preprint":false},{"pmid":"34023356","id":"PMC_34023356","title":"NFKB2 inhibits NRG1 transcription to affect nucleus pulposus cell degeneration and inflammation in intervertebral disc degeneration.","date":"2021","source":"Mechanisms of ageing and development","url":"https://pubmed.ncbi.nlm.nih.gov/34023356","citation_count":15,"is_preprint":false},{"pmid":"30927119","id":"PMC_30927119","title":"Fatal Enteroviral Encephalitis in a Patient with Common Variable Immunodeficiency Harbouring a Novel Mutation in NFKB2.","date":"2019","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30927119","citation_count":15,"is_preprint":false},{"pmid":"38990428","id":"PMC_38990428","title":"Clinical, Immunological, and Genetic Features in Patients with NFKB1 and NFKB2 Mutations: a Systematic Review.","date":"2024","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38990428","citation_count":14,"is_preprint":false},{"pmid":"9264393","id":"PMC_9264393","title":"Germline configuration of nfkb2, c-rel and bcl3 in childhood acute lymphoblastic leukemia (ALL).","date":"1997","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/9264393","citation_count":14,"is_preprint":false},{"pmid":"30941333","id":"PMC_30941333","title":"Severe Facial Herpes Vegetans and Viremia in NFKB2-Deficient Common Variable Immunodeficiency.","date":"2019","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/30941333","citation_count":13,"is_preprint":false},{"pmid":"32813180","id":"PMC_32813180","title":"A Nonsense N -Terminus NFKB2 Mutation Leading to Haploinsufficiency in a Patient with a Predominantly Antibody Deficiency.","date":"2020","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32813180","citation_count":11,"is_preprint":false},{"pmid":"30863427","id":"PMC_30863427","title":"A Novel Monoallelic Nonsense Mutation in the NFKB2 Gene Does Not Cause a Clinical Manifestation.","date":"2019","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30863427","citation_count":10,"is_preprint":false},{"pmid":"29658079","id":"PMC_29658079","title":"TNFα-Induced Expression of Transport Protein Genes in HUVEC Cells Is Associated with Enhanced Expression of Transcription Factor Genes RELB and NFKB2 of the Non-Canonical NF-κB Pathway.","date":"2018","source":"Bulletin of experimental biology and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29658079","citation_count":10,"is_preprint":false},{"pmid":"10398801","id":"PMC_10398801","title":"Genomic organization and chromosomal mapping of mouse nuclear factor kappa B 2 (NFKB2).","date":"1999","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/10398801","citation_count":10,"is_preprint":false},{"pmid":"40187604","id":"PMC_40187604","title":"TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells.","date":"2025","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/40187604","citation_count":9,"is_preprint":false},{"pmid":"29285709","id":"PMC_29285709","title":"Effects of dried tofu supplementation during interval walking training on the methylation of the NFKB2 gene in the whole blood of older women.","date":"2017","source":"The journal of physiological sciences : JPS","url":"https://pubmed.ncbi.nlm.nih.gov/29285709","citation_count":9,"is_preprint":false},{"pmid":"33688203","id":"PMC_33688203","title":"MiRNA-223-3p Affects Mantle Cell Lymphoma Development by Regulating the CHUK/NF-ƘB2 Signaling Pathway.","date":"2021","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33688203","citation_count":8,"is_preprint":false},{"pmid":"28190248","id":"PMC_28190248","title":"Opposing roles of Nfkb2 gene products p100 and p52 in the regulation of breast cancer stem cells.","date":"2017","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/28190248","citation_count":8,"is_preprint":false},{"pmid":"10830747","id":"PMC_10830747","title":"Normal structure of NFKB2, C-REL and BCL-3 gene loci in lymphoproliferative and myeloproliferative disorders.","date":"2000","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/10830747","citation_count":8,"is_preprint":false},{"pmid":"30953794","id":"PMC_30953794","title":"Pathogenic NFKB2 variant in the ankyrin repeat domain (R635X) causes a variable antibody deficiency.","date":"2019","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/30953794","citation_count":8,"is_preprint":false},{"pmid":"30500415","id":"PMC_30500415","title":"Early B cell developmental impairment with progressive B cell deficiency in NFKB2 mutated CVID disease without autoimmunity.","date":"2018","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/30500415","citation_count":7,"is_preprint":false},{"pmid":"34609106","id":"PMC_34609106","title":"Disseminated Coccidioidomycosis as the First Presentation of a C-Terminal NFKB2 Pathogenic Variant: A Case Report and Review of the Literature.","date":"2022","source":"The Pediatric infectious disease journal","url":"https://pubmed.ncbi.nlm.nih.gov/34609106","citation_count":7,"is_preprint":false},{"pmid":"36555871","id":"PMC_36555871","title":"Altered mRNA Expression of NFKB1 and NFKB2 Genes in Penile Lichen Sclerosus, Penile Cancer and Zoon Balanitis.","date":"2022","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36555871","citation_count":6,"is_preprint":false},{"pmid":"29693141","id":"PMC_29693141","title":"Analysis of NFKB2‑mediated regulation of mechanisms underlying the development of Hodgkin's lymphoma.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/29693141","citation_count":6,"is_preprint":false},{"pmid":"31177178","id":"PMC_31177178","title":"ECCR1 and NFKB2 Polymorphisms as Potential Biomarkers of Non-small Cell Lung Cancer in a Polish Population.","date":"2019","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31177178","citation_count":6,"is_preprint":false},{"pmid":"12697057","id":"PMC_12697057","title":"Refined physical map of the human PAX2/HOX11/NFKB2 cancer gene region at 10q24 and relocalization of the HPV6AI1 viral integration site to 14q13.3-q21.1.","date":"2003","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/12697057","citation_count":6,"is_preprint":false},{"pmid":"39447838","id":"PMC_39447838","title":"Type-Specific Impacts of Protein Defects in Pathogenic NFKB2 Variants: Novel Clinical Findings From 138 Patients.","date":"2024","source":"The journal of allergy and clinical immunology. In practice","url":"https://pubmed.ncbi.nlm.nih.gov/39447838","citation_count":5,"is_preprint":false},{"pmid":"9523851","id":"PMC_9523851","title":"Interleukin-1 increases expression of the LYT-10 (NFkappaB2) proto-oncogene/transcription factor in renal cell carcinoma lines.","date":"1998","source":"The Journal of laboratory and clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9523851","citation_count":5,"is_preprint":false},{"pmid":"39607428","id":"PMC_39607428","title":"Modeling corticotroph deficiency with pituitary organoids supports the functional role of NFKB2 in human pituitary differentiation.","date":"2024","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/39607428","citation_count":4,"is_preprint":false},{"pmid":"39846017","id":"PMC_39846017","title":"Se-methylselenocysteine inhibits inflammatory response in an LPS-stimulated chicken HD11 macrophage-like cell model through the NFKB2 pathway.","date":"2025","source":"Frontiers in veterinary science","url":"https://pubmed.ncbi.nlm.nih.gov/39846017","citation_count":4,"is_preprint":false},{"pmid":"31150062","id":"PMC_31150062","title":"Central Diabetes Insipidus in a Patient With NFKB2 Mutation: Expanding the Endocrine Phenotype in DAVID Syndrome.","date":"2019","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31150062","citation_count":4,"is_preprint":false},{"pmid":"39579251","id":"PMC_39579251","title":"A Novel Heterozygous NFKB2 Variant in a Multiplex Family with Common Variable Immune Deficiency and Autoantibodies Against Type I IFNs.","date":"2024","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39579251","citation_count":3,"is_preprint":false},{"pmid":"39091795","id":"PMC_39091795","title":"TRAIL-induced cytokine production via NFKB2 pathway promotes neutrophil chemotaxis and immune suppression in triple negative breast cancers.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39091795","citation_count":3,"is_preprint":false},{"pmid":"33824054","id":"PMC_33824054","title":"Important role of Nfkb2 in the KrasG12D-driven carcinogenesis in the pancreas.","date":"2021","source":"Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/33824054","citation_count":3,"is_preprint":false},{"pmid":"7510259","id":"PMC_7510259","title":"Isolation of a cDNA encoding the chicken p50B/p97 (Lyt-10) transcription factor.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/7510259","citation_count":3,"is_preprint":false},{"pmid":"35916405","id":"PMC_35916405","title":"Nfkb2 deficiency and its impact on plasma cells and immunoglobulin expression in murine small intestinal mucosa.","date":"2022","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/35916405","citation_count":2,"is_preprint":false},{"pmid":"39589533","id":"PMC_39589533","title":"Effects of high-pressure-processed rice intake during interval walking training on glycemic control and NFKB2 gene methylation in hyperglycemic older people.","date":"2024","source":"European journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/39589533","citation_count":2,"is_preprint":false},{"pmid":"40027254","id":"PMC_40027254","title":"A dataset on NFKB1/NFKB2 knockout Jurkat cells and primary CD4+ T cells generated by CRISPR/Cas9 mediated gene disruption.","date":"2025","source":"Data in brief","url":"https://pubmed.ncbi.nlm.nih.gov/40027254","citation_count":2,"is_preprint":false},{"pmid":"37781189","id":"PMC_37781189","title":"Case Report: Mycosis fungoides as an exclusive manifestation of common variable immunodeficiency in a family with a NFKB2 gene mutation.","date":"2023","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37781189","citation_count":2,"is_preprint":false},{"pmid":"40590069","id":"PMC_40590069","title":"Genetic and Functional Dissection of the NFKB2 Gene: Implications for Milk Fatty Acid Biosynthesis in Dairy Cattle.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/40590069","citation_count":1,"is_preprint":false},{"pmid":"39405181","id":"PMC_39405181","title":"Intrinsic functional defects in B cells of patients with NFKB2 mutations.","date":"2025","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39405181","citation_count":1,"is_preprint":false},{"pmid":"41040843","id":"PMC_41040843","title":"Single-Cell Transcriptomic Analysis Highlights the Impact of NFKB2-Mediated MIF-CD44 Signaling Axis in Endometrioid Endometrial Cancer.","date":"2025","source":"International journal of women's health","url":"https://pubmed.ncbi.nlm.nih.gov/41040843","citation_count":0,"is_preprint":false},{"pmid":"41838238","id":"PMC_41838238","title":"B3GNT3 facilitates NFKB2 processing and non-canonical NF-κB activation to drive lung adenocarcinoma progression.","date":"2026","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/41838238","citation_count":0,"is_preprint":false},{"pmid":"41608586","id":"PMC_41608586","title":"PLK1 stabilizes β-catenin to drive colorectal carcinogenesis through NFKB2-mediated transcriptional activation of USP2a and site-specific phosphorylation.","date":"2026","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/41608586","citation_count":0,"is_preprint":false},{"pmid":"40165201","id":"PMC_40165201","title":"Case report: novel NFKB2 variant associated with pediatric eosinophilic granulomatosis with polyangiitis (EGPA) in the COVID-19 pandemic.","date":"2025","source":"Pediatric rheumatology online journal","url":"https://pubmed.ncbi.nlm.nih.gov/40165201","citation_count":0,"is_preprint":false},{"pmid":"31305727","id":"PMC_31305727","title":"Erratum: NFKB2 mutation in common variable immunodeficiency and isolated adrenocorticotropic hormone deficiency: A case report and review of literature: Erratum.","date":"2017","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31305727","citation_count":0,"is_preprint":false},{"pmid":"32901356","id":"PMC_32901356","title":"Correction to: A Nonsense N -Terminus NFKB2 Mutation Leading to Haploinsufficiency in a Patient with a Predominantly Antibody Deficiency.","date":"2020","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32901356","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.15.682509","title":"The MUC1 extracellular domain and cytoplasmic tail play distinct roles during  <i>Salmonella</i>  invasion of enterocytes","date":"2025-10-15","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.15.682509","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.23.634426","title":"Depicting pathogenesis of osteomyelitis by single cell RNA-sequencing and an involvement of  <i>Morrbid</i>  in the autoinflammatory disease","date":"2025-01-26","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.23.634426","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.19.644147","title":"Spatial Transcriptomics Identifies Immune-Stromal Niches Associated with Cancer in Adult Dermatomyositis","date":"2025-03-19","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.19.644147","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.11.617591","title":"Phosphoproteomics highlights complex resource management upon inflammatory stimulation of fibroblasts","date":"2024-10-11","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.11.617591","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50267,"output_tokens":6224,"usd":0.12208,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14964,"output_tokens":5305,"usd":0.103722,"stage2_stop_reason":"end_turn"},"total_usd":0.225802,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"The LYT-10 (NFKB2) protein contains an N-terminal rel (DNA-binding) domain homologous to NF-κB p50, a poly-G region, and C-terminal ankyrin-like repeat domains. The ankyrin domain inhibits DNA binding in vitro; removal of the ankyrin domain activates DNA binding to κB sequences. Chromosomal translocation-generated LYT-10–Cα1 fusion retains the rel domain, lacks the ankyrin domain, and binds κB sequences constitutively.\",\n      \"method\": \"cDNA cloning, in vitro DNA-binding assay (EMSA), domain deletion analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro DNA-binding reconstitution with domain deletion, foundational paper replicated by multiple subsequent studies\",\n      \"pmids\": [\"1760839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"NF-κB p100 (NFKB2/Lyt-10) functions as an IκB-like molecule: it is localized in the cytoplasm of HeLa cells where it associates with c-Rel, p50, and p65 (RelA), and its overexpression sequesters p65 in the cytoplasm, reducing nuclear p65 DNA-binding activity. p100 is also a component of the MHC class I transcription factor H2TF1.\",\n      \"method\": \"Subcellular fractionation, immunoblotting, EMSA, transient transfection reporter assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (fractionation, EMSA, co-immunoprecipitation, reporter assay), replicated across labs\",\n      \"pmids\": [\"8413211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"H2TF1, the ubiquitous MHC class I κB enhancer-binding factor, is the full-length p100 product (NF-κB2 p100) encoded by nfkb2. Purified H2TF1 binds the MHC κB site with high affinity (KD = 3 × 10⁻¹¹ M), contradicting earlier reports that p100 did not bind DNA.\",\n      \"method\": \"Affinity chromatography purification, peptide sequencing, specific antiserum reactivity, in vitro DNA-binding assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — protein purified to homogeneity, identified by peptide sequencing and specific antiserum, in vitro binding assay with KD determination\",\n      \"pmids\": [\"8360178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"NFKB2 p49/p52 forms a heterodimer with RelA (p65) that binds the HIV κB site with ~6-fold higher affinity (KD = 11.8 pM) than p49 homodimer alone (KD = 69.1 pM). The p49/p65 heterodimer stimulates in vitro transcription 18-fold. IκB-α (MAD-3) inhibits DNA binding of p49/p65 and p50/p65 heterodimers but stimulates binding of p49 or p50 alone.\",\n      \"method\": \"Scatchard analysis, in vitro transcription assay, recombinant protein binding assays, transient transfection\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — quantitative binding constants determined, in vitro transcription reconstituted, multiple methods in single rigorous study\",\n      \"pmids\": [\"8441377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"C-terminal truncations of NFKB2 found in lymphoid malignancies (p84/85 in HUT78 T-cell lymphoma) result in constitutive nuclear localization of the unprocessed protein, altered NF-κB complex composition, and loss of transcriptional repressor function; the truncated proteins bind κB sites but cannot repress NF-κB-mediated transcription.\",\n      \"method\": \"Northern blot, immunoprecipitation, EMSA, immunofluorescence, transient co-transfection reporter assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods, replicated across multiple laboratories with analogous tumor-derived constructs\",\n      \"pmids\": [\"8208540\", \"8036016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"NFKB2 p100 is constitutively cytoplasmic; TPA-induced NF-κB activation causes cytoplasmic-to-nuclear translocation of the processed p52 form. p52 alone preferentially binds H2/HLA-κB sites over HIV/IgK-κB sites, but efficiently binds both when heterodimerized with RelA (p65). p52 homodimers have no intrinsic transactivation; they down-regulate p65-driven transcription, whereas p65/p52 heterodimers stimulate it.\",\n      \"method\": \"Immunofluorescence, EMSA, transient co-transfection reporter assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct localization experiments with functional consequence, EMSA binding specificity, reporter assays; replicated by multiple groups\",\n      \"pmids\": [\"8108136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"In HTLV-I–infected and Tax-expressing cells, NFKB2 (p100) is overexpressed and physically associated with c-Rel and with the Tax protein. Tax-dependent processing of p100 to p52 correlates with constitutive nuclear NF-κB activity, suggesting Tax drives NFKB2 processing as a mechanism of constitutive NF-κB activation.\",\n      \"method\": \"Co-immunoprecipitation, immunoblotting, EMSA\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-immunoprecipitation showing physical association, single lab, correlative processing data\",\n      \"pmids\": [\"8108127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Tumor-associated NFKB2 mutants (p85 and lyt-10Cα) lacking the ankyrin domain are constitutively nuclear, bind κB sites in unprocessed form, activate transcription via heterodimerization with RelA/p65, and have lost the transcriptional repression activity of normal p52. They can independently transactivate κB reporter genes in a manner not further stimulated by Bcl-3.\",\n      \"method\": \"Immunofluorescence, UV-crosslinking immunoprecipitation of DNA-protein adducts, transient co-transfection reporter assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal functional assays (localization, DNA binding, transcriptional activation/repression), replicated across labs\",\n      \"pmids\": [\"7651435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Overexpressed p100 (NFKB2) in human breast cancer cells sequesters p50/p65 heterodimers in the cytoplasm via co-immunoprecipitation, acting as a cytoplasmic IκB-like inhibitor; most p65 is complexed with p100 rather than IκB-α in high-p100 cells.\",\n      \"method\": \"Co-immunoprecipitation, immunoblotting, subcellular fractionation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-immunoprecipitation from endogenous proteins in cell lines, consistent with mechanistic model from other studies\",\n      \"pmids\": [\"7478612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The NFKB2 promoter contains six κB sites (five capable of binding NF-κB complexes in vitro). RelA transactivates the NFKB2 promoter in a dose-dependent manner, while NF-κB p52 acts as a repressor of its own gene promoter, establishing a negative feedback regulatory circuit.\",\n      \"method\": \"EMSA, transient transfection with CAT reporter, co-transfection with NF-κB effector plasmids\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter-reporter and EMSA experiments, single lab\",\n      \"pmids\": [\"7541912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"p52 is generated principally by cotranslational proteasomal processing of p100, dependent on a glycine-rich region (GRR) upstream of the p52 C-terminus; repositioning the GRR alters the site of proteasome cleavage. Sequences downstream of the GRR, flanking the processing site, confer the characteristically inefficient p52 generation from p100 compared to the balanced p50/p105 processing of NFKB1.\",\n      \"method\": \"p100/p105 chimera constructs, proteasome inhibitor experiments, immunoblotting, in vitro translation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — biochemical reconstitution with chimeric constructs and domain repositioning establishing mechanistic determinants of processing\",\n      \"pmids\": [\"10597218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"p100 assembles into high-molecular-weight complexes in the cytoplasm that bind NF-κB subunits in two modes: (1) direct dimerization via Rel homology domains and (2) interaction of p100 ankyrin repeats with preformed NF-κB dimers, thereby mediating bona fide IκBδ activity. These complexes regulate all NF-κB isoforms.\",\n      \"method\": \"Biochemical characterization of endogenous cytoplasmic complexes, purified recombinant protein reconstitution, gel filtration, immunoprecipitation\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — both endogenous and purified recombinant proteins used, multiple binding modes identified biochemically, rigorous reconstitution\",\n      \"pmids\": [\"19524538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A point mutation in Nfkb2 that prevents processing of p100 to p52 generates a 'super-repressor' phenotype: signaling through the noncanonical pathway is ablated due to p52 absence, causing disorganized splenic architecture and disrupted B cell development. Furthermore, the unprocessed p100 interacts with RelA, preventing RelA dimer activation in response to both canonical and noncanonical stimuli, resulting in defective lymph node formation and altered bone homeostasis.\",\n      \"method\": \"Mouse genetic model (knock-in point mutation), immunoblotting, histological analysis, signaling assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — defined genetic model with specific molecular and cellular phenotypic readouts, establishes p100 as inhibitor of RelA\",\n      \"pmids\": [\"18025196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SCF(Fbw7) is the E3 ubiquitin ligase that governs ubiquitination and proteasomal destruction of NFkB2/p100 in a GSK3-dependent manner. In Fbw7-null cells, elevated p100 reduces NFkB signaling and increases TNFα-induced cell death; reintroduction of wild-type but not disease-derived mutant Fbw7 rescues NFkB activity. T cell-specific Fbw7 depletion reduces NFkB activity and perturbs T cell differentiation.\",\n      \"method\": \"Genetic knockout cells (Fbw7-/-), immunoblotting, ubiquitination assay, T cell-specific conditional knockout mouse model\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function genetic model, rescue with wild-type vs. mutant Fbw7, in vivo T cell model, multiple orthogonal methods\",\n      \"pmids\": [\"22708077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Heterozygous C-terminal frameshift and nonsense mutations in NFKB2 (p.Lys855Serfs*7 and p.Arg853*) affect phosphorylation and proteasomal processing of p100, blocking p52 nuclear translocation. This establishes the noncanonical NF-κB signaling pathway as a genetic cause of common variable immunodeficiency.\",\n      \"method\": \"Exome sequencing, immunoblot analysis, immunofluorescence microscopy of patient B cells\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct functional analysis of patient-derived cells with two orthogonal methods (immunoblot and immunofluorescence), replicated in subsequent studies\",\n      \"pmids\": [\"24140114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A missense mutation (D865G) in NFKB2 causes failure of p100 phosphorylation, blocking its processing to p52 and disrupting both canonical and noncanonical NF-κB pathways; this leads to severe mature and transitional B-cell deficiency.\",\n      \"method\": \"Western blotting, immunophenotyping, patient-derived cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional demonstration of phosphorylation failure and processing block in patient cells, single lab\",\n      \"pmids\": [\"25237204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"An 8 bp C-terminal frameshift deletion in NFKB2 (p.Asp865Valfs*17) mutates Ser866 to Arg, leaving p100 unphosphorylated at this critical regulatory position, thereby abrogating p100 processing and nuclear translocation of p52.\",\n      \"method\": \"Western blot, Sanger sequencing, flow cytometry (B cell immunophenotyping), patient cell analysis\",\n      \"journal\": \"Journal of clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphorylation and processing defects demonstrated directly in patient cells, identifies specific regulatory phosphorylation site\",\n      \"pmids\": [\"24888602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NF-κB2/p52 directly transcriptionally activates EZH2 expression in melanoma cells. Inhibition of the noncanonical NF-κB pathway by targeting NF-kB2/p52 or the upstream kinase NIK decreases EZH2, restoring the senescence program. Overexpression of NF-kB2/p52 in normal melanocytes prevents stress- and oncogene-induced senescence.\",\n      \"method\": \"siRNA knockdown, overexpression, mouse xenograft models, ChIP/transcriptional activation assays (implied by direct transcriptional activation claim)\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional loss-of-function and gain-of-function with defined cellular phenotype (senescence), in vivo validation, single lab\",\n      \"pmids\": [\"26364600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Novel nonsense NFKB2 mutations within the Rel homology domain (E418X and R635X) cause constitutive nuclear localization of truncated proteins and activation of both canonical and noncanonical NF-κB pathways, distinct from C-terminal mutations that produce unprocessable p100 super-repressor.\",\n      \"method\": \"Flow cytometry, immunoblotting, immunohistochemistry, luciferase reporter assay, real-time PCR, multiplex cytokine assay in transfected HEK293T cells and patient PBMCs\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods including functional reporter assays and patient cell studies, defines distinct gain-of-function mechanism\",\n      \"pmids\": [\"28778864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Nfkb2-mediated noncanonical signaling in intestinal epithelial cells escalates the RelA-driven proinflammatory gene response by supplementing latent NF-κB dimers to the canonical module, exacerbating inflammatory cell infiltration and colon pathologies. Cell-autonomous Nfkb2 signaling increases available latent NF-κB dimers, linking noncanonical signaling to canonical RelA-driven inflammation.\",\n      \"method\": \"Mouse model of experimental colitis, conditional intestinal epithelial cell-specific genetic manipulation, mechanistic studies of latent dimer supplementation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in cell-specific mouse model, defined molecular mechanism (latent dimer supplementation), specific phenotypic readout\",\n      \"pmids\": [\"34155144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Severe p100-degradation resistance (due to mutations in the p100 degron required for signal-dependent degradation) causes thymic medullary hypoplasia and autoimmune disease, while absence of both p100 and p52 does not. Autoimmunity arises from the IκB function of degradation-resistant p100 in nonhematopoietic cells, not from p52 deficiency.\",\n      \"method\": \"Mouse genetic models with graded degron mutations, thymic histology, T cell receptor repertoire analysis, bone marrow transplantation\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple allelic series establishing mechanistic hierarchy, epistasis with p100-/- mice, nonhematopoietic cell function established by transplantation\",\n      \"pmids\": [\"33107914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NFKB2 mutations directly impair human pituitary corticotroph development: pituitary organoids derived from CRISPR/Cas9-edited hiPSCs harboring DAVID patient NFKB2 mutations show changes in pituitary progenitor genes (HESX1, PITX1, LHX3), hypothalamic secreted factors (BMP4, FGF8, FGF10), lineage precursor genes (TBX19, POU1F1), and corticotroph terminal differentiation markers (PCSK1, POMC), with drastic reduction in corticotroph numbers.\",\n      \"method\": \"CRISPR/Cas9-edited human iPSC-derived pituitary organoids, gene expression analysis\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR-edited human disease model with specific molecular readouts, establishes direct causal role of NFKB2 in pituitary differentiation\",\n      \"pmids\": [\"39607428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"B3GNT3 physically interacts with NFKB2/p100 and facilitates its phosphorylation, processing into p52, and nuclear accumulation, thereby activating noncanonical NF-κB signaling. This interaction is independent of B3GNT3 glycosyltransferase activity. Genetic ablation of NFKB2 reverses the oncogenic effects of B3GNT3.\",\n      \"method\": \"Co-immunoprecipitation coupled with mass spectrometry, co-IP, catalytic inactive mutant of B3GNT3, NFKB2 knockout, immunoblotting, xenograft models\",\n      \"journal\": \"Cellular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP with MS identification, catalytic mutant analysis, genetic rescue, single lab\",\n      \"pmids\": [\"41838238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TRAIL-induced cytokine production (CXCLs 1, 2, 3, 8, 11 and IL-6) in triple negative breast cancer cells is mediated predominantly through death receptor 5, caspase-8, and the noncanonical NFKB2 pathway. These cytokines promote neutrophil chemotaxis and immune suppression. In vivo TRAIL treatment activates the NFkB2 pathway, elevates cytokine production, and increases neutrophil tumor recruitment.\",\n      \"method\": \"RNAseq, siRNA knockdown, in vitro neutrophil chemotaxis assays, TNBC xenograft mouse models, immunoblotting\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway knockdown with defined cytokine readout, in vivo validation, multiple cell lines tested, single lab\",\n      \"pmids\": [\"40187604\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NFKB2 encodes the precursor p100 and processed p52: p100 contains an N-terminal rel/DNA-binding domain and C-terminal ankyrin repeats that function as an IκBδ-like inhibitor by sequestering NF-κB dimers (including RelA) in the cytoplasm as part of high-molecular-weight complexes; signal-dependent phosphorylation at C-terminal sites (including Ser866) triggers GSK3-dependent recognition by the SCF(Fbw7) E3 ligase and proteasomal processing that releases p52, which translocates to the nucleus as an active transcription factor preferentially forming heterodimers with RelB or RelA to activate κB target genes; p52 also auto-represses NFKB2 transcription via a negative feedback loop; C-terminal truncating mutations abolish the ankyrin/IκBδ function producing constitutively nuclear, constitutively active oncoproteins, while specific C-terminal phosphorylation-site mutations generate non-processable p100 super-repressors that block both canonical and noncanonical NF-κB signaling, causing immunodeficiency (CVID/DAVID syndrome) and autoimmunity through degradation-resistant p100 IκBδ activity in nonhematopoietic cells including thymic stroma and pituitary progenitors.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NFKB2 encodes a bifunctional NF-\\u03baB precursor, p100, whose N-terminal Rel homology domain confers \\u03baB-site DNA binding while its C-terminal ankyrin repeats act as an intramolecular and intermolecular I\\u03baB-like inhibitor [#0, #1]. In its full-length cytoplasmic form, p100 (identical to the MHC class I enhancer factor H2TF1) sequesters NF-\\u03baB subunits including c-Rel, p50, and RelA/p65, both by direct Rel-domain dimerization and by capturing preformed dimers through its ankyrin repeats\\u2014the basis of its bona fide I\\u03baB\\u03b4 activity within high-molecular-weight complexes that restrain all NF-\\u03baB isoforms [#1, #2, #8, #11]. Signal-dependent processing removes the ankyrin domain to release the active p52 subunit: p52 has no intrinsic transactivation and homodimers repress transcription, but p52/RelA heterodimers bind \\u03baB sites with high affinity and strongly activate transcription [#3, #5]. Processing proceeds via cotranslational proteasomal cleavage gated by a glycine-rich region [#10] and is controlled by C-terminal phosphorylation (including Ser866) that licenses GSK3-dependent, SCF(Fbw7)-mediated ubiquitination and degradation of the inhibitory C-terminus [#13, #16]. p52 also represses the NFKB2 promoter, forming a negative feedback loop that opposes RelA-driven transactivation of the gene [#9]. Two distinct classes of disease-causing mutation illustrate this architecture: C-terminal truncating or phosphorylation-site mutations that block processing generate degradation-resistant p100 \\\"super-repressors\\\" which inhibit RelA and ablate both canonical and noncanonical signaling [#12, #14, #20], whereas Rel-domain nonsense mutations remove the ankyrin domain to yield constitutively nuclear, transcriptionally active species [#7, #18]. NFKB2 mutations cause common variable immunodeficiency, and the I\\u03baB\\u03b4 activity of degradation-resistant p100 in nonhematopoietic cells\\u2014including thymic stroma and pituitary corticotroph progenitors\\u2014drives autoimmunity and the endocrine features of DAVID syndrome [#14, #20, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Established the domain logic of NFKB2: an N-terminal Rel DNA-binding domain held in check by C-terminal ankyrin repeats, answering how one gene product could be both a transcription factor and an inhibitor.\",\n      \"evidence\": \"cDNA cloning and in vitro EMSA with domain deletions; translocation-derived ankyrin-less fusion\",\n      \"pmids\": [\"1760839\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve how the ankyrin domain is removed in cells\", \"No in vivo processing mechanism\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Defined p100 as a cytoplasmic I\\u03baB-like sequestering molecule and identified it as the MHC class I enhancer factor H2TF1, reconciling its inhibitory and DNA-binding identities.\",\n      \"evidence\": \"Subcellular fractionation, co-IP, EMSA, affinity purification with peptide sequencing and KD determination in HeLa cells\",\n      \"pmids\": [\"8413211\", \"8360178\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the signal that releases sequestered dimers\", \"Endogenous complex stoichiometry unresolved\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Showed that processed p52 acquires activating function only through heterodimerization, distinguishing repressive homodimers from transactivating p52/RelA complexes.\",\n      \"evidence\": \"Scatchard analysis, in vitro transcription, recombinant binding assays\",\n      \"pmids\": [\"8441377\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vitro affinities not linked to cellular target gene selectivity\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Demonstrated that signal-induced processing converts cytoplasmic p100 to nuclear p52, and that tumor-derived C-terminal truncations abolish repression while remaining DNA-binding\\u2014linking ankyrin loss to oncogenic constitutive activity.\",\n      \"evidence\": \"Immunofluorescence, EMSA, reporter assays, tumor-derived constructs (HUT78 p84/85)\",\n      \"pmids\": [\"8108136\", \"8208540\", \"8036016\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Processing protease and signaling input not yet identified\", \"Mechanism of constitutive nuclear retention undefined\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Connected viral oncogenesis to NFKB2, showing HTLV-I Tax associates with p100 and drives its processing to sustain constitutive NF-\\u03baB activity.\",\n      \"evidence\": \"Co-IP, immunoblotting, EMSA in Tax-expressing cells\",\n      \"pmids\": [\"8108127\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Correlative processing data, single lab\", \"Direct Tax-induced cleavage not reconstituted\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identified the NFKB2 promoter negative feedback loop\\u2014RelA activates the gene while p52 represses it\\u2014explaining homeostatic control of pathway output.\",\n      \"evidence\": \"EMSA and CAT reporter co-transfection with NF-\\u03baB effectors\",\n      \"pmids\": [\"7541912\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab promoter-reporter assays\", \"In vivo relevance of feedback not tested\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined the cis-determinants of inefficient p100 processing, showing a glycine-rich region directs cotranslational proteasomal cleavage and flanking sequences limit p52 yield.\",\n      \"evidence\": \"p100/p105 chimeras, proteasome inhibitors, in vitro translation\",\n      \"pmids\": [\"10597218\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the E3 ligase or signal that triggers processing\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Resolved the biochemical basis of I\\u03baB\\u03b4 activity, showing p100 forms high-MW complexes binding NF-\\u03baB via two modes (Rel dimerization and ankyrin capture of preformed dimers) that regulate all isoforms.\",\n      \"evidence\": \"Endogenous complex characterization, recombinant reconstitution, gel filtration, IP\",\n      \"pmids\": [\"19524538\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural model of the complex not determined\", \"Dynamics of release upon signaling not captured\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Established in vivo that unprocessable p100 acts as a super-repressor of RelA, demonstrating p100 inhibits canonical as well as noncanonical signaling and is required for lymphoid organ development.\",\n      \"evidence\": \"Nfkb2 processing-deficient knock-in mouse, histology, signaling assays\",\n      \"pmids\": [\"18025196\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphorylation/degron details of the block not molecularly mapped\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified SCF(Fbw7) as the GSK3-dependent E3 ligase governing p100 degradation, closing the loop from C-terminal phosphorylation to proteasomal turnover.\",\n      \"evidence\": \"Fbw7-null cells, ubiquitination assays, rescue with WT vs mutant Fbw7, T cell conditional knockout\",\n      \"pmids\": [\"22708077\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise phosphodegron residues recognized by Fbw7 not fully enumerated\", \"Kinase upstream of GSK3 priming not defined here\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established NFKB2 C-terminal mutations as a genetic cause of common variable immunodeficiency by showing they block p100 phosphorylation, processing, and p52 nuclear translocation.\",\n      \"evidence\": \"Exome sequencing, immunoblot and immunofluorescence of patient B cells\",\n      \"pmids\": [\"24140114\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific contributions to disease not dissected in patients\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Pinpointed Ser866 as the critical regulatory phosphorylation site, with missense and frameshift mutations abolishing its phosphorylation to block processing and cause B-cell deficiency.\",\n      \"evidence\": \"Western blot, immunophenotyping, Sanger sequencing of patient cells (D865G; D865Vfs*17)\",\n      \"pmids\": [\"25237204\", \"24888602\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab patient analyses\", \"Kinase phosphorylating Ser866 not identified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Distinguished a second mutational class\\u2014Rel-domain nonsense mutations\\u2014that produce constitutively nuclear gain-of-function proteins activating both pathways, contrasting with C-terminal loss-of-function super-repressors.\",\n      \"evidence\": \"Reporter assays, immunoblot, IHC, cytokine assays in HEK293T and patient PBMCs (E418X, R635X)\",\n      \"pmids\": [\"28778864\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Clinical penetrance differences between mutation classes not fully resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established that degradation-resistant p100, not p52 loss, drives autoimmunity, acting through I\\u03baB function in nonhematopoietic cells and causing thymic medullary hypoplasia.\",\n      \"evidence\": \"Graded degron-mutant mouse allelic series, thymic histology, TCR repertoire, bone marrow transplantation\",\n      \"pmids\": [\"33107914\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific thymic stromal targets of p100 I\\u03baB activity not enumerated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed noncanonical Nfkb2 signaling amplifies canonical RelA-driven inflammation by supplying latent NF-\\u03baB dimers, providing a crosstalk mechanism in intestinal epithelium.\",\n      \"evidence\": \"Intestinal epithelial cell-specific conditional mouse colitis model with epistasis analysis\",\n      \"pmids\": [\"34155144\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of dimer supplementation to human disease unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated a direct, cell-autonomous role for NFKB2 in human pituitary corticotroph development, explaining the endocrine features of DAVID syndrome.\",\n      \"evidence\": \"CRISPR-edited DAVID-mutant hiPSC pituitary organoids, gene expression analysis\",\n      \"pmids\": [\"39607428\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets of NFKB2 in corticotrophs not mapped\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Linked NFKB2 to tumor immune evasion, showing TRAIL/DR5/caspase-8 signaling engages the noncanonical pathway to drive chemokine production and neutrophil recruitment in TNBC.\",\n      \"evidence\": \"RNAseq, siRNA knockdown, chemotaxis assays, TNBC xenografts, immunoblot\",\n      \"pmids\": [\"40187604\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study\", \"Direct NFKB2-driven chemokine gene occupancy not shown\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Identified B3GNT3 as a noncatalytic interactor that promotes p100 phosphorylation and processing, defining a new upstream activator of noncanonical signaling in cancer.\",\n      \"evidence\": \"Reciprocal co-IP/MS, catalytic-inactive B3GNT3 mutant, NFKB2 knockout rescue, xenografts\",\n      \"pmids\": [\"41838238\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; mechanism by which B3GNT3 promotes phosphorylation undefined\", \"Reciprocal validation in physiological context limited\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The identity of the kinase that phosphorylates Ser866 to prime SCF(Fbw7) recognition, and the structural basis of p100 I\\u03baB\\u03b4 high-MW complexes, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ser866 kinase not identified in the corpus\", \"No structural model of the p100\\u2013NF-\\u03baB inhibitory complex\", \"Tissue-specific nonhematopoietic target genes incompletely defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3, 5, 9, 17]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 3, 5]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 8, 11, 12]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [1, 8, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 5, 8, 11]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 5, 7, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 12, 19]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 5, 9, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [12, 14, 19, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [14, 18, 20, 21]}\n    ],\n    \"complexes\": [\"NF-\\u03baB p52/RelA heterodimer\", \"p100 I\\u03baB\\u03b4 high-molecular-weight complex\", \"H2TF1\"],\n    \"partners\": [\"RELA\", \"RELB\", \"REL\", \"NFKB1\", \"FBXW7\", \"B3GNT3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}